Building Better CARs: Advancing Dual-Targeting Discovery

If you are working on cell therapies, you know that the development and success of next generation cell therapies hinges on increasing the accessibility, tolerability, and affordability to expand patient access.

Thinking about these considerations during your discovery stage can help provide advances in the use of Chimeric Antigen Receptor (CAR) technology. With the latest dual-targeting CAR applications, we can now more accurately target cancer cells and deliver patients allogenic treatments with reduced side effects and improved outcomes.

Join this webinar and hear how Century Therapeutics accomplished this through design and development of a novel, dual-targeting CAR for their allogeneic IPS cell derived iT platform. You will gain an understanding of:

• How an antibody discovery program can identify new cell therapies for hematologic cancers
• How adding off-target screening to an antibody discovery program earlier in the process can provide valuable insights and accelerate candidate selection
• What challenges and considerations went into the design of the VHH antibody discovery programs for Century Therapeutic’s therapeutic vision

Webinar Presenters

Jill Carton, PhD
Executive Director of CAR Engineering and Protein Sciences
Century Therapeutics

Renny Feldman, PhD
Site Head and Director of Antibody Discovery
Charles River

Have a scheduling conflict? Sign up even if you can’t make it; we’ll share the recording after.